Dasatinib 50mg tablet

Dasatinib 50 mg tablet is a prescription oral kinase inhibitor medication (also referred to as Sprycel) prescribed for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in cases of Ph+.

Main indication DASATINIB TABLET Therapy of Ph+ CML and Ph+ ALL. Application role: It is indicated for use in patients either newly diagnosed with the disease or resistant to other types of treatment including imatinib. Drug class: Tyrosine kinase inhibitor (TKI) which targets BCR-ABL, SRC, and certain other kinases.

How to administer: Taken orally, in one piece, with or DASATINIB 50MG TABLET IN PAKISTAN without food; it must not be chewed, split, or ground. Dosage schedule: It is determined solely by an oncologist depending on the stage of the disease in the patient and his/her body measurements. Precaution: Due to being an antineoplastic medication, any crushed or broken tablets should be handled with extreme care to prevent contact with the drug.

Side effects: They include myelosuppression (decreased number of white blood cells, red blood cells, or platelets), bleeding and fluid retention (for example, pleural effusion). Monitoring: It requires periodic analysis of complete blood counts and assessment of liver and lung functions.

Dasatinib belongs to the group of kinase inhibitors. It prevents the activity of an abnormal protein which causes multiplication of cancer cells.